180 Life Sciences (ATNF) announced that the United States Patent and Trademark Office has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction. The newly allowed patent covers a method for reducing POCD – particularly POCD manifested as delirium – by administering an anti-Human tumor necrosis factor Alpha monoclonal antibody to the patient in a therapeutically effective amount commencing just before and during the surgical procedure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATNF: